Publication | Closed Access
GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma
24
Citations
14
References
2020
Year
Neuro-oncologyGliomaPromising Immunotherapeutic ApproachImmunologyMalignant GliomaImmune Checkpoint InhibitorImmunotherapeuticsTumor TargetingAnti-cancer AgentDinutuximab BetaCancer TreatmentMedicineRadiation OncologyTumor Microenvironment
| Year | Citations | |
|---|---|---|
Page 1
Page 1